Abstract
Neurodegenerative disease affects tens of millions of people, worldwide, and comes at a cost to the public of billions of dollars. Stem cell therapy, in recent years, has generated a lot of enthusiasm as a novel treatment for neurodegenerative disease. In particular, Parkinson’s disease has been identified as the ideal neurodegenerative disease to be treated using stem cells. Despite years of setbacks, recent experimental results have renewed optimism in the validity of stem cell therapy for the treatment of Parkinson’s disease. In this review, we discuss advances in our understanding of the embryonic development of the dopamine system and the importance of these discoveries in the continued efforts towards stem cell therapy for Parkinson’s disease.
Keywords: Dopamine neuron, embryonic stem cells, neural development, neurodegeneration, Parkinson’s disease, stem cell therapy, dopamine system, hemiparkinsonian, motoneurons, oligodendrocytes
CNS & Neurological Disorders - Drug Targets
Title:From Stem Cells to Dopamine Neurons: Developmental Biology Meets Neurodegeneration
Volume: 11 Issue: 7
Author(s): Jignesh Tailor, Thomas Andreska and Raja Kittappa
Affiliation:
Keywords: Dopamine neuron, embryonic stem cells, neural development, neurodegeneration, Parkinson’s disease, stem cell therapy, dopamine system, hemiparkinsonian, motoneurons, oligodendrocytes
Abstract: Neurodegenerative disease affects tens of millions of people, worldwide, and comes at a cost to the public of billions of dollars. Stem cell therapy, in recent years, has generated a lot of enthusiasm as a novel treatment for neurodegenerative disease. In particular, Parkinson’s disease has been identified as the ideal neurodegenerative disease to be treated using stem cells. Despite years of setbacks, recent experimental results have renewed optimism in the validity of stem cell therapy for the treatment of Parkinson’s disease. In this review, we discuss advances in our understanding of the embryonic development of the dopamine system and the importance of these discoveries in the continued efforts towards stem cell therapy for Parkinson’s disease.
Export Options
About this article
Cite this article as:
Tailor Jignesh, Andreska Thomas and Kittappa Raja, From Stem Cells to Dopamine Neurons: Developmental Biology Meets Neurodegeneration, CNS & Neurological Disorders - Drug Targets 2012; 11 (7) . https://dx.doi.org/10.2174/1871527311201070893
DOI https://dx.doi.org/10.2174/1871527311201070893 |
Print ISSN 1871-5273 |
Publisher Name Bentham Science Publisher |
Online ISSN 1996-3181 |
Call for Papers in Thematic Issues
Diagnosis and treatment of central nervous system infectious diseases
Infectious diseases of the central nervous system (CNS) can be divided into bacterial, tuberculous, viral, fungal, parasitic infections, etc. Early etiological treatment is often the most crucial means to reduce the mortality rate of patients with central nervous system infections, reduce complications and sequelae, and improve prognosis. The initial clinical ...read more
Trends and perspectives in the rational management of CNS disorders
Central nervous system (CNS) diseases enforce a significant global health burden, driving ongoing efforts to improve our understanding and effectiveness of therapy. This issue investigates current advances in the discipline, focusing on the understanding as well as therapeutic handling of various CNS diseases. The issue covers a variety of diseases, ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Genetic Factors in Parkinsons Disease and Potential Therapeutic Targets
Current Neuropharmacology Unraveling Monoamine Receptors Involved in the Action of Typical and Atypical Antipsychotics on Glutamatergic and Serotonergic Transmission in Prefrontal Cortex
Current Pharmaceutical Design Thioridazine: The Good and the Bad
Recent Patents on Anti-Infective Drug Discovery mGlu5, Dopamine D<sub>2</sub> and Adenosine A<sub>2A</sub> Receptors in L-DOPA-induced Dyskinesias
Current Neuropharmacology Organoselenium Compounds as Potential Neuroprotective Therapeutic Agents
Current Organic Chemistry Herb-Drug Interactions in Neurological Disorders: A Critical Appraisal
Current Drug Metabolism A Review of Voltammetric Methods for Determination of Dopamine Agonists
Current Analytical Chemistry A Comparison Between Quetiapine and Aripiprazole for Treatment of Schizophrenia: A Double Blind Contrast
Current Psychopharmacology 5'-Nucleotidases, Nucleosides and their Distribution in the Brain: Pathological and Therapeutic Implications
Current Medicinal Chemistry Pharmacogenetics and Drug Therapy in Psychiatry - The Role of the CYP2D6 Polymorphism
Current Pharmaceutical Design Adjunctive Depot Antipsychotic in Treatment-Resistant Schizophrenia
Current Psychopharmacology Gene Transfer to the Central Nervous System: Current State of the Art of the Viral Vectors
Current Genomics Restless Legs Syndrome/Willis-Ekbom Disease and Periodic Limb Movements: A Comprehensive Review of Epidemiology, Pathophysiology, Diagnosis and Treatment Considerations
Current Rheumatology Reviews Partial Dopamine Agonists and the Treatment of Psychosis
Current Neuropharmacology Drugs Treatment of Pain in Multiple Sclerosis
Current Clinical Pharmacology Novel Technologies for Dipeptide Drugs Design and their Implantation
Current Pharmaceutical Design Animal Models for Parkinson's Disease
CNS & Neurological Disorders - Drug Targets Effects of Eugenol on the Central Nervous System: Its Possible Application to Treatment of Alzheimers Disease, Depression, and Parkinsons Disease
Current Bioactive Compounds Alzheimer’s Disease and Autistic Spectrum Disorder: Is there any Association?
CNS & Neurological Disorders - Drug Targets Naturalistic Studies of Second Generation Antipsychotics in the Treatment of Schizophrenia
Current Medicinal Chemistry